Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Department of Pathology, Hebei Cancer Hospital, Shijiazhuang, Hebei, 050200, China.
Cell Death Dis. 2021 May 12;12(5):472. doi: 10.1038/s41419-021-03754-0.
Small-cell carcinoma of the esophagus (SCCE) is a rare and aggressive cancer. Although several consistent genomic changes were observed previously between SCCE and small-cell lung cancer (SCLC), detailed mutational landscapes revealing discrepancies in genetic underpinnings of tumorigenesis between these two cancers are scarce, and little attention has been paid to answer whether these genetic alterations were related to the prognosis. Herein by performing whole-exome sequencing of 48 SCCE and 64 SCLC tumor samples, respectively we have shown that the number of driver mutations in SCCE was significantly lower than in SCLC (p = 0.0042). In SCCE, 46% of recurrent driver mutations were clonal, which occurred at an early stage during tumorigenesis, while 16 driver mutations were found clonal in SCLC. NOTCH1/3, PIK3CA, and ATM were specifically clonal in SCCE, while TP53 was clonal in SCLC. The total number of clonal mutations differed between two cancers and presented lower in SCCE compared to SCLC (p = 0.0036). Moreover, overall survival (OS) was shorter in patients with higher numbers of clonal mutations for both cancers. In summary, SCCE showed distinct mutational background and clonal architecture compared with SCLC. Organ-specific clonal events revealed different molecular mechanisms underlying tumorigenesis, tumor development, patients' prognosis, and possible variations in therapeutic outcomes to candidate treatments.
食管小细胞癌 (SCCE) 是一种罕见且侵袭性强的癌症。虽然此前在 SCCE 和小细胞肺癌 (SCLC) 之间观察到了一些一致的基因组变化,但揭示这两种癌症在肿瘤发生的遗传基础上存在差异的详细突变图谱却很少,而且很少有人关注这些遗传改变是否与预后有关。在此,我们通过对 48 例 SCCE 和 64 例 SCLC 肿瘤样本进行全外显子组测序,结果表明 SCCE 中的驱动突变数量明显低于 SCLC(p=0.0042)。在 SCCE 中,46%的复发性驱动突变是克隆的,这些突变发生在肿瘤发生的早期阶段,而在 SCLC 中发现了 16 个克隆驱动突变。NOTCH1/3、PIK3CA 和 ATM 特异性在 SCCE 中为克隆,而 TP53 在 SCLC 中为克隆。两种癌症的克隆突变总数不同,SCCE 中的突变总数明显低于 SCLC(p=0.0036)。此外,两种癌症的患者中,克隆突变数量越多,总体生存率 (OS) 越短。总之,SCCE 与 SCLC 相比具有明显不同的突变背景和克隆结构。器官特异性的克隆事件揭示了肿瘤发生、肿瘤发展、患者预后以及对候选治疗方法的可能治疗效果的不同分子机制。